Faron Pharmaceuticals Oy
Company Profile
Business description
Faron Pharmaceuticals Oy is a clinical-stage biopharmaceutical company developing novel treatments for medical conditions with unmet needs. The company has a pipeline based on the receptors involved in the regulation of immune response in oncology and organ damage. Clevegen (bexmarilimab), its investigative precision immunotherapy in phase I/II development as a novel macrophage checkpoint immunotherapy for patients with untreatable solid tumours, is a novel anti-Clever-1 antibody with the ability to switch immune suppression to immune activation. Traumakine, the company's investigational intravenous interferon beta-1a is an anti-viral and anti-inflammatory agent, being tested for the prevention of complications that arise from cytokine release syndrome, or hyperinflammatory conditions.
Contact
Joukahaisenkatu 6 B
Turku20520
FINT: +358 24695151
E: investor.relations@faron.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
25
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 7,913.90 | 352.20 | 4.66% |
| CAC 40 | 7,215.65 | 352.63 | 5.14% |
| DAX 40 | 20,728.73 | 1,057.85 | 5.38% |
| Dow JONES (US) | 40,608.45 | 2,962.86 | 7.87% |
| FTSE 100 | 7,999.35 | 319.87 | 4.17% |
| HKSE | 20,681.78 | 417.29 | 2.06% |
| NASDAQ | 17,124.97 | 1,857.06 | 12.16% |
| Nikkei 225 | 34,609.00 | 2,894.97 | 9.13% |
| NZX 50 Index | 12,201.43 | 394.88 | 3.34% |
| S&P 500 | 5,456.90 | 0.00 | 0.00% |
| S&P/ASX 200 | 7,709.60 | 334.60 | 4.54% |
| SSE Composite Index | 3,223.64 | 36.83 | 1.16% |